Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients
Federica Miglietta(Peter MacCallum Cancer Centre), Grazia Arpino(University of Naples Federico II), Carlo Buonerba(CTO Andrea Alesini), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmine De Angelis(Baylor College of Medicine), Filippo Montemurro(Roche (Switzerland)), Emilio Bria(Università Cattolica del Sacro Cuore), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Valentina Guarneri(Istituto Oncologico Veneto), Letizia Pontolillo(Università Cattolica del Sacro Cuore), Giampaolo Tortora(University of Naples Federico II), Annarita Verrazzo(Scuola Superiore Meridionale), Giuseppe Di Lorenzo(Saint Camillus International University of Health and Medical Sciences), Mario Giuliano(Regione Campania), Rossana Di Rienzo(University of Naples Federico II), Lucia Del Mastro(Ospedale Policlinico San Martino), Fabio Puglisi(University of Udine), Luca Scafuri(CTO Andrea Alesini), Monica Mariño(University of Padua)
Cited by 9
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830